title: [Mortality of patients who are older than 75 years after ST elevation myocardial infarction in clinical practice].
abstract: BACKGROUND
  Patients who are older than 75 years are often excluded in clinical trials evaluating therapies for ST elevation myocardial infarction. Therefore there is a lack of prospective data for this steadily increasing number of elderly patients.
  
  
  METHODS
  Between 07/2000 and 11/2002 a total of 16 823 patients with acute coronary syndromes in 154 hospitals were enrolled in the ACOS registry, with 8309 having a STEMI. Baseline characteristics, therapies during the hospital course and at discharge, hospital-mortality and 1-year mortality were prospectively collected. In this study we analysed the outcome of patients older than 75 years with STEMI of less than 24 duration.
  
  
  RESULTS
  A total of 2045 patients > 75 years (median age 80.1 years, 53.9 % women) were included. Of the latter 51 % were treated conservatively, 19 % with fibrinolysis and 30 % with primary PCI. In-hospital mortality in the three groups was 23.4 %, 25.4 % und 10.2 %, while total mortality after one year was 52.4 %, 41.3 % und 19.3 %, respectively. In the multivariate analysis both primary PCI (odds ratio 0.36, 95 % CI 0.25 - 0.52) and fibrinolysis (odds ratio 0.65, 95 % CI 0.44 - 0.97) where associated with a lower mortality after discharge.
  
  
  CONCLUSIONS
  Hospital- as well as 1-year mortality in patients with STEMI who are older than 75 years are high. Primary PCI is associated with a decrease of in-hospital and 1-year mortality, while fibrinolysis improves mortality after discharge. Therefore early reperfusion therapy, preferably with primary PCI should be considered in elderly patients, after taking in count biological age and major comorbidities.
authors.affiliation: Herzzentrum Ludwigshafen, Medizinische Klinik B. Uwe.Zeymer@t-online.de
authors.forename: U
authors.initials: U
authors.lastname: Zeymer
authors.forename: A
authors.initials: A
authors.lastname: Gitt
authors.forename: R
authors.initials: R
authors.lastname: Winkler
authors.forename: R
authors.initials: R
authors.lastname: Zahn
authors.forename: C
authors.initials: C
authors.lastname: Jünger
authors.forename: R
authors.initials: R
authors.lastname: Schiele
authors.forename: M
authors.initials: M
authors.lastname: Gottwik
authors.forename: J
authors.initials: J
authors.lastname: Senges
mesh_terms: D000208:Acute Disease; D000359:Aftercare; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary; D002317:Cardiovascular Agents / Q000627:therapeutic use; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy; D016017:Odds Ratio; D011446:Prospective Studies; D012008:Recurrence; D012042:Registries; D012307:Risk Factors; D016019:Survival Analysis; D015912:Thrombolytic Therapy; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents